小剂量地西他滨联合CAG化疗方案治疗MDS患者的可行性及对疾病缓解率、血清学相关指标变化的影响  

Feasibility of low-dose decitabine combined with CAG chemotherapy in the treatment of MDS patients and its effect on disease remission rate and serological related indexes

作　　者：贾佩佩 Jia Peipei(Department of Hematology,Xintai People's Hospital,Taian,Shandong 271200,China)

机构地区：[1]山东省新泰市人民医院,山东泰安271200

出　　处：《首都食品与医药》2024年第13期83-86,共4页Capital Food Medicine

摘　　要：目的探究小剂量地西他滨联合CAG化疗方案治疗骨髓增生异常综合征(MDS)患者的可行性,分析其对疾病缓解率、血清学相关指标变化的影响情况。方法选取2021年9月-2023年8月新泰市人民医院血液内科接收的MDS患者100例,按照入院先后顺序将其分为对照组(2021年9月-2022年8月,n=49)与研究组(2022年9月-2023年8月,n=51)。对照组实施CAG化疗方案治疗,研究组在对照组基础上加用小剂量地西他滨治疗,比较两组治疗第90天疾病缓解率、血清学相关指标[血清可溶性CD44(sCD44)、生长分化因子11(GDF11)]水平及治疗期间不良反应发生率。结果治疗第90天,研究组疾病缓解率较对照组更高(P<0.05)。治疗第90天,两组血清sCD44、GDF11水平均低于治疗第1天,且与对照组比较,研究组血清sCD44、GDF11水平均更低(P<0.05)。治疗期间,研究组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。结论对MDS患者实施小剂量地西他滨联合CAG化疗方案治疗,有助于提高患者疾病缓解率,改善血清学相关指标,且不会增加不良反应发生率,其在MDS患者治疗方面具有一定的可行性。Objective To explore the feasibility of low-dose decitabine combined with CAG chemotherapy in the treatment of patients with myelodysplastic syndrome(MDS),and to analyze its effects on disease response rate and serological related indicators.Methods A total of 100 MDS patients admitted to the Department of Hematology of Xintai People's Hospital from September 2021 to August 2023 were selected and divided into control group(September 2021 to August 2022,n=49)and study group(September 2022 to August 2023,n=51)according to the order of admission.The control group was treated with CAG chemotherapy,and the study group was treated with lowdose decitabine on the basis of the control group.The disease response rate at the 90th day of treatment,the levels of serological related indicators[serum soluble CD44(sCD44),growth differentiation factor 11(GDF11)]and the incidence of adverse reactions during treatment were compared between the two groups.Results On the 90th day of treatment,the remission rate of the study group was higher than that of the control group(P<0.05).On the 90th day of treatment,serum sCD44 and GDF11 levels in both groups were lower than those on the 1st day of treatment,and compared with the control group,serum sCD44 and GDF11 levels in the study group were lower(P<0.05).During treatment,there was no significant difference in the incidence of adverse reactions between the study group and the control group(P>0.05).Conclusion The implementation of low-dose decitabine combined with CAG chemotherapy regimen in MDS patients can help to improve the disease remission rate of patients,improve the changes of serological related indicators,and will not increase the incidence of adverse reactions,which has certain feasibility in the treatment of MDS patients.

关 键 词：地西他滨 CAG化疗方案 骨髓增生异常综合征 疾病缓解率 不良反应发生率 

分 类 号：R733.71[医药卫生—肿瘤]